- |||||||||| DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Enrollment open: Post Marketing Surveillance (PMS) Study of Ryzodeg (clinicaltrials.gov) - Aug 29, 2016 P=N/A, N=1000, Enrolling by invitation, Active, not recruiting --> Enrolling by invitation
- |||||||||| tibulizumab (ZB-106) / Zura Bio
Trial primary completion date: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Aug 29, 2016 P1, N=32, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Jan 2018
- |||||||||| dimethyl fumarate / Generic mfg.
Trial completion, Review, Enrollment change, Trial primary completion date: REALIZE: Tecfidera Lymphocyte Chart Review (clinicaltrials.gov) - Aug 26, 2016 P=N/A, N=483, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | N=1500 --> 483 | Trial primary completion date: Nov 2015 --> Feb 2016
- |||||||||| Trial completion, Phase classification, Enrollment change, Trial primary completion date: Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (clinicaltrials.gov) - Aug 25, 2016
P1, N=36, Completed, N=50 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Aug 2016 Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011
- |||||||||| Enrollment closed, Enrollment change: ENHANCE: MS Symptom Management Study (clinicaltrials.gov) - Aug 24, 2016
P=N/A, N=37, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=30 --> 37
- |||||||||| Humira (adalimumab) / AbbVie
Trial primary completion date, Real-world evidence, Real-world: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan (clinicaltrials.gov) - Aug 23, 2016 P=N/A, N=100, Recruiting, Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Nov 2016 --> Jan 2018
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=34, Terminated, Recruiting --> Completed N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution.
- |||||||||| Orencia (abatacept) / BMS
Trial primary completion date: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (clinicaltrials.gov) - Aug 22, 2016 P=N/A, N=370, Active, not recruiting, N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution. Trial primary completion date: Jun 2016 --> Sep 2016
- |||||||||| Trial primary completion date: NeuroSenSS: Primary Sj (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=55, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- |||||||||| Trial initiation date, Trial primary completion date: DiaCon Dual-Hormone Closed-Loop Glucose Control (clinicaltrials.gov) - Aug 16, 2016
P2/3, N=13, Not yet recruiting, Active, not recruiting --> Completed Initiation date: May 2016 --> Oct 2016 | Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Telehealth Intervention for Youth With T1DM (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=32, Completed, Recruiting --> Completed Recruiting --> Completed | N=110 --> 32 | Trial primary completion date: Dec 2014 --> May 2014
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: RICE: Remission by Intra-articular Injection Plus CErtolizumab (clinicaltrials.gov) - Aug 13, 2016 P2, N=48, Recruiting, Recruiting --> Completed | N=110 --> 32 | Trial primary completion date: Dec 2014 --> May 2014 Trial primary completion date: Dec 2016 --> Dec 2017
|